<DOC>
	<DOCNO>NCT03004417</DOCNO>
	<brief_summary>Effect CHF 6001 biomarkers inflammation induce sputum blood , pulmonary function symptom benefit comparison placebo .</brief_summary>
	<brief_title>Pharmacodynamics , Pharmacokinetics Safety Two Doses CHF6001 DPI Subjects With Moderate , Severe COPD</brief_title>
	<detailed_description>The purpose study obtain information effect two dos CHF6001 sputum blood biomarkers inflammation subject symptomatic COPD moderate , severe airflow limitation chronic bronchitis . The efficacy treatment also measure use force oscillometry technique spirometry . Safety , tolerability pharmacokinetics evaluate .</detailed_description>
	<criteria>Male female age ≥40 year A female eligible enter study nonchildbearing potential i.e . physiologically incapable become pregnant Women physiologically capable become pregnant ( i.e . woman childbearing potential ) eligible enter study negative pregnancy test screen agree use one follow highly effective contraceptive measure Subjects establish diagnosis COPD ( accord GOLD guideline , update 2015 ) least 12 month prior screen visit With smoke history least 10 packyears [ packyears=number cigarette per day x number years/20 ] . Current ex smoker eligible . With BMI range 1835 Kg/m2 With postbronchodilator FEV1 ≥30 % ≤70 % Subjects must receive daily maintenance triple therapy ( ICS plus LABA plus LAMA ) stable dose dose regimen , least 2 month prior screen With history chronic bronchitis define chronic cough sputum production three month per year two year know 'spontaneous sputum producer ' subject Subjects must symptomatic screening define CAT score ≥10 Subjects must able train correctly use DPI inhaler They must cooperative attitude ability perform require outcome measurement ( e.g . spirometry test , induced sputum ... ) . Pregnant lactate female subject Subjects current diagnosis asthma Subjects moderate severe COPD exacerbation [ i.e . result use systemic ( oral/IV/IM corticosteroid ) and/or antibiotic hospitalisation ] low respiratory tract infection within 6 week prior study entry screen period Subjects maintenance bronchodilator therapy ( LABA alone , LAMA alone , dual LABA/LAMA alone ) maintenance dual therapy ( ICS/LABA ICS plus LAMA ) within 2 month prior study entry Subjects PDE4 inhibitor ( e.g . roflumilast ) within 2 month prior study entry Subjects require longterm ( least 12 hour daily ) oxygen therapy chronic hypoxemia ; participate pulmonary rehabilitation programme complete programme within last 6 week prior study entry Subjects know respiratory disorder COPD ... Subjects lung cancer history lung cancer active cancer history cancer ( lung ) less 5 year disease free survival time Subjects know history hypersensitivity beta2agonist , PDE4 inhibitors excipients contain formulation use trial Subjects diagnosis depression associate suicidal ideation behaviour diagnosis generalise anxiety disorder investigator 's opinion would place patient risk Subjects know history clinically significant cardiovascular condition , limit , unstable acute ischemic heart disease within one year prior study entry , NYHA Class III/IV heart failure , know history sustain nonsustained cardiac arrhythmia history atrial fibrillation diagnose last 6 month prior study entry control therapy rate control strategy Subjects unstable concurrent disease Subjects clinically significant laboratory abnormality Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) Subjects receive treatment drug know welldefined potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) within previous 3 month prior study entry screen period Subjects experience excessive weight loss recently ( explained natural course COPD know background condition ) . Subjects history alcohol abuse and/or substance/drug abuse within 12 month prior screen visit Subjects receive investigational drug within precede 30 day ( 60 day biologics ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>